The content of our website is not intended for persons resident, or partnerships or corporations organised or incorporated inside the United States (“US Residents”). UBP does not market, solicit or promote its services inside the jurisdiction of the United States at any time. The content provided on the UBP website is intended to be used for general information purposes only. Therefore, nothing on this website is to be construed as an investment recommendation or an offer to buy or sell any security...
Equity Analyst
Genève, Suisse
Anglais, Français
Pierre is a Healthcare Investment Specialist in UBP’s Advisory Services team in Geneva, which he joined in 2019.
Pierre brings 20 years of experience in both equity markets and medical science. Prior to joining UBP, Pierre worked for 13 years as a sell-side life sciences analyst in Paris for different brokers and notably participated in the IPO of Moderna at the end of 2018. Before moving to finance, Pierre worked as a scientist specialised in molecular biology and virology for the Pasteur Institute in Hong Kong and for a privately-held biotech company in France.
Pierre is a graduate of the Grenoble Ecole de Management in Grenoble, and also holds a degree in Molecular and Cellular Biology from the University Joseph Fourier, both in Grenoble.
22.11.2021
In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.
14.04.2021
UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.
